Characteristics of COVID-19 Pneumonia Cases Treated withFavipiravir in the Chest Diseases Clinic
Yıl: 2021 Cilt: 35 Sayı: 2 Sayfa Aralığı: 75 - 81 Metin Dili: İngilizce DOI: 10.5222/IGH.2021.47965 İndeks Tarihi: 17-11-2021
Characteristics of COVID-19 Pneumonia Cases Treated withFavipiravir in the Chest Diseases Clinic
Öz: Objective: There is currently no specific treatment for COVID-19. Favipiravir treatment has been shown to be effective in in-vitro and pre-clinical trials in the treatment of COVID-19. In this study, we aimed to present the characteristics and treatment results of our patients who were hospitalized with the diagnosis of COVID-19 pneumonia and received favipiravir treatment in the chest diseases clinics of our hospital. Method: The database created by the COVID-19 Study Group of our hospital consisting of the data of patients diagnosed with COVID-19 who applied to our hospital between March 11, 2020 and May 15, 2020 was examined. 471 patients enrolled in the database and 412 hospitalized patients were evaluated and included in 38 patients in whom favipiravir was used for treatment in the chest diseases clinic. Treatments, drug doses, initiation time of favipiravir, clinical and radiological responses to treatment were analyzed retrospectively. Fever control, improvement of respiratory failure, improvement in laboratory values, and absence of radiological deterioration were accepted as response criteria to treatment.Results: It was observed that 30 of 38 patients who were given favipiravir treatment in the chest diseases clinic were successfully discharged. Eight patients whose general condition deteriorated despite favipiravir treatment in the clinic and who had an indication for intensive care were transferred to intensive care. Three of these eight patients died and 5 of them were successfully discharged.Conclusion: Mortality rate was found to be 7.9% in COVID-19 cases who received favipiravir treatment in our chest diseases clinic. After the favipiravir treatment started to be used more effectively in our country, it was observed that transfers to intensive care units decreased and mortality decreased. Therefore, although favipiravir is thought to be effective in the treatment of COVID-19 infection, further prospective controlled studies are needed.
Anahtar Kelime: Göğüs Hastalıkları Kliniğinde Favipiravir Kullandığımız COVID-19 Pnömonisi Olgularımızın Özellikleri
Öz: maç: COVID-19 tedavisine yönelik onaylanmış spesifik antiviral tedavi bulunmamaktadır. Daha önceinfluenza ve ebolavirüse karşı kullanılan favipiravir, nükleik asit analoğu ve ribonukleik asit (RNA) bağımlıRNA polimeraz inhibitörü bir ön ilaç olarak, COVID-19 enfeksiyonunda önerilen antiviral tedavi seçenekleriarasındadır. Göğüs hastalıkları kliniklerimizde, tedavisinde favipiravir kullandığımız COVID-19 pnömoniliolguları demografik, klinik ve radyolojik özelliklerine göre incelemeyi, tedavi yanıtlarını değerlendirmeyiamaçladık.Yöntem: Hastanemiz COVID-19 Çalışma Grubu tarafından 11 Mart 2020-15 Mayıs 2020 tarihleri arasındahastanemize başvuran COVID-19 tanılı hastaların verilerinden oluşturulmuş olan veri tabanı incelendi. Veritabanına kayıtlı 471 hasta içinden yatarak tedavi alan 412 hastanın verileri değerlendirildi ve göğüshastalıkları kliniğinde tedavide favipiravir kullanılan 38 olgunun klinik takipleri sırasında aldıkları tedaviler,ilaç dozları, favipiravir başlanma zamanı, tedaviye klinik ve radyolojik yanıtları retrospektif olarakincelendi. Ateş kontrolü, varsa solunum yetmezliğinin düzelmesi, laboratuvar değerlerindeki iyileşme,radyolojik kötüleşme olmaması tedaviye yanıt kriterleri olarak kabul edildi.Bulgular: Göğüs hastalıkları servisinde favipiravir tedavisi verilen 38 hastanın 30’unun başarıyla taburcuedildiği görüldü. Serviste yatarken favipiravir başlanmasına rağmen genel durumu bozulan ve yoğunbakım endikasyonu doğan 8 hastanın yoğun bakıma nakli yapıldı. Bu 8 hastanın 3’ü vefat etti ve 5’ibaşarıyla taburcu edildi.Sonuç: Çalışmamızda göğüs hastalıkları kliniğinde favipiravir tedavisi alan COVID-19 olgularında mortaliteoranı %7.9 olarak bulunmuştur. Favipiravir tedavisinin ülkemizde daha etkin bir şekilde kullanılmayabaşlanmasının ardından yoğun bakım nakillerinin azaldığı ve mortalitenin düştüğü gözlenmiştir. Bu nedenlefavipiravirin COVID-19 enfeksiyonun tedavisinde etkin olduğu düşünülmekle birlikte ileri prospektifkontrollü çalışmalara ihtiyaç vardır.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Zunyou Wu and McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72.314 cases from the Chinese Center for Disease Control and Prevention. Jama 323. 2020;13:1239-42. https://doi.org/10.1001/jama.2020.2648
- 2. Hoffmann C. Treatment. In: Kamps BS, Hoffmann C, eds. Covid Reference, Edition 2020-2. SteinHauser Verlag; Amedeo, Germany; 2020. Website www.covidreference.com [accessed 12 April 2020].
- 3. Du, Yin-Xiao, and Xiao-Ping Chen. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019- nCoV infection. Clinical Pharmacology & Therapeutics (2020). https://doi.org/10.1002/cpt.1844
- 4. Kimiyasu K and Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacology & Therapeutics 2020:107512. https://doi.org/10.1016/j.pharmthera.2020.107512
- 5. Daouda S, et al. Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS medicine 13.3 2016:e1001967. https://doi.org/10.1371/journal.pmed.1002066
- 6. Ministry of Health (2020). COVID-19 Yeni Koronavirüs Hastalığı [online]. Website: https://covid19bilgi.saglik. gov.tr/ tr/ [accessed 17April 2020].
- 7. Vincent M et al. Ebola virus dynamics in mice treated with favipiravir. Antiviral Research 2015;123:70-7. https://doi.org/10.1016/j.antiviral.2015.08.015
- 8. Manli W, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019- nCoV) in vitro. Cell Research 2020;30(3):269-71. https://doi.org/10.1038/s41422-020-0282-0
- 9. Rong-Hui D, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2. European Respiratory Journal 56.3 (2020). https://doi.org/10.1183/13993003.00524-2020
- 10. Qingxian C, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering 2020. https://doi.org/10.1016/j.eng.2020.03.007
- 11. Chang C, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. MedRxiv (2020). https://doi.org/10.1101/2020.03.17.20037432
- 12. Ivashchenko AA, et al. AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II/III multicenter randomized clinical trial. medRxiv (2020). https://doi.org/10.1093/cid/ciaa1176
- 13. Shrestha, Dhan Bahadur, et al. “Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis.” Virology Journal 17.1 2020:1-15. https://doi.org/10.21203/rs.3.rs-40775/v1
- 14. World Health Organization, WHO Coronavirus Disease (COVID-19) Dashboard, Data last updated: 2020/7/15.
- 15. CDC COVID-19 Response Team, Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID19) - United States, February 12-March 16, 2020, MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-6. https://doi.org/10.15585/mmwr.mm6912e2
| APA | çırak a, Hakoglu B, Polat G, Varol Y, AYRANCI A, Karadeniz G, Özkan S, MERTOĞLU A, YALNIZ E, Tuksavul F, Yılmaz C (2021). Characteristics of COVID-19 Pneumonia Cases Treated withFavipiravir in the Chest Diseases Clinic. , 75 - 81. 10.5222/IGH.2021.47965 |
| Chicago | çırak ali kadri,Hakoglu Burcin,Polat Gulru,Varol Yelda,AYRANCI AYSU,Karadeniz Gülistan,Özkan Serir,MERTOĞLU AYDAN,YALNIZ ENVER,Tuksavul Fevziye,Yılmaz Celalettin Characteristics of COVID-19 Pneumonia Cases Treated withFavipiravir in the Chest Diseases Clinic. (2021): 75 - 81. 10.5222/IGH.2021.47965 |
| MLA | çırak ali kadri,Hakoglu Burcin,Polat Gulru,Varol Yelda,AYRANCI AYSU,Karadeniz Gülistan,Özkan Serir,MERTOĞLU AYDAN,YALNIZ ENVER,Tuksavul Fevziye,Yılmaz Celalettin Characteristics of COVID-19 Pneumonia Cases Treated withFavipiravir in the Chest Diseases Clinic. , 2021, ss.75 - 81. 10.5222/IGH.2021.47965 |
| AMA | çırak a,Hakoglu B,Polat G,Varol Y,AYRANCI A,Karadeniz G,Özkan S,MERTOĞLU A,YALNIZ E,Tuksavul F,Yılmaz C Characteristics of COVID-19 Pneumonia Cases Treated withFavipiravir in the Chest Diseases Clinic. . 2021; 75 - 81. 10.5222/IGH.2021.47965 |
| Vancouver | çırak a,Hakoglu B,Polat G,Varol Y,AYRANCI A,Karadeniz G,Özkan S,MERTOĞLU A,YALNIZ E,Tuksavul F,Yılmaz C Characteristics of COVID-19 Pneumonia Cases Treated withFavipiravir in the Chest Diseases Clinic. . 2021; 75 - 81. 10.5222/IGH.2021.47965 |
| IEEE | çırak a,Hakoglu B,Polat G,Varol Y,AYRANCI A,Karadeniz G,Özkan S,MERTOĞLU A,YALNIZ E,Tuksavul F,Yılmaz C "Characteristics of COVID-19 Pneumonia Cases Treated withFavipiravir in the Chest Diseases Clinic." , ss.75 - 81, 2021. 10.5222/IGH.2021.47965 |
| ISNAD | çırak, ali kadri vd. "Characteristics of COVID-19 Pneumonia Cases Treated withFavipiravir in the Chest Diseases Clinic". (2021), 75-81. https://doi.org/10.5222/IGH.2021.47965 |
| APA | çırak a, Hakoglu B, Polat G, Varol Y, AYRANCI A, Karadeniz G, Özkan S, MERTOĞLU A, YALNIZ E, Tuksavul F, Yılmaz C (2021). Characteristics of COVID-19 Pneumonia Cases Treated withFavipiravir in the Chest Diseases Clinic. İzmir Göğüs Hastanesi Dergisi, 35(2), 75 - 81. 10.5222/IGH.2021.47965 |
| Chicago | çırak ali kadri,Hakoglu Burcin,Polat Gulru,Varol Yelda,AYRANCI AYSU,Karadeniz Gülistan,Özkan Serir,MERTOĞLU AYDAN,YALNIZ ENVER,Tuksavul Fevziye,Yılmaz Celalettin Characteristics of COVID-19 Pneumonia Cases Treated withFavipiravir in the Chest Diseases Clinic. İzmir Göğüs Hastanesi Dergisi 35, no.2 (2021): 75 - 81. 10.5222/IGH.2021.47965 |
| MLA | çırak ali kadri,Hakoglu Burcin,Polat Gulru,Varol Yelda,AYRANCI AYSU,Karadeniz Gülistan,Özkan Serir,MERTOĞLU AYDAN,YALNIZ ENVER,Tuksavul Fevziye,Yılmaz Celalettin Characteristics of COVID-19 Pneumonia Cases Treated withFavipiravir in the Chest Diseases Clinic. İzmir Göğüs Hastanesi Dergisi, vol.35, no.2, 2021, ss.75 - 81. 10.5222/IGH.2021.47965 |
| AMA | çırak a,Hakoglu B,Polat G,Varol Y,AYRANCI A,Karadeniz G,Özkan S,MERTOĞLU A,YALNIZ E,Tuksavul F,Yılmaz C Characteristics of COVID-19 Pneumonia Cases Treated withFavipiravir in the Chest Diseases Clinic. İzmir Göğüs Hastanesi Dergisi. 2021; 35(2): 75 - 81. 10.5222/IGH.2021.47965 |
| Vancouver | çırak a,Hakoglu B,Polat G,Varol Y,AYRANCI A,Karadeniz G,Özkan S,MERTOĞLU A,YALNIZ E,Tuksavul F,Yılmaz C Characteristics of COVID-19 Pneumonia Cases Treated withFavipiravir in the Chest Diseases Clinic. İzmir Göğüs Hastanesi Dergisi. 2021; 35(2): 75 - 81. 10.5222/IGH.2021.47965 |
| IEEE | çırak a,Hakoglu B,Polat G,Varol Y,AYRANCI A,Karadeniz G,Özkan S,MERTOĞLU A,YALNIZ E,Tuksavul F,Yılmaz C "Characteristics of COVID-19 Pneumonia Cases Treated withFavipiravir in the Chest Diseases Clinic." İzmir Göğüs Hastanesi Dergisi, 35, ss.75 - 81, 2021. 10.5222/IGH.2021.47965 |
| ISNAD | çırak, ali kadri vd. "Characteristics of COVID-19 Pneumonia Cases Treated withFavipiravir in the Chest Diseases Clinic". İzmir Göğüs Hastanesi Dergisi 35/2 (2021), 75-81. https://doi.org/10.5222/IGH.2021.47965 |
